<DOC>
	<DOCNO>NCT02934698</DOCNO>
	<brief_summary>This postmarketing N 2 study design evaluate efficacy safety open-label ivacaftor treatment two sister cystic fibrosis pancreatic sufficiency .</brief_summary>
	<brief_title>An Efficacy Safety Study Ivacaftor Patients With Cystic Fibrosis Two Splicing Mutations</brief_title>
	<detailed_description>The two sister splice mutation predict respond favorably ivacaftor therapy . In addition measurement usual clinical outcome ( i.e . lung function , nutritional status ) , great interest impact nontuberculous mycobacteria ( NTM ) airways infection . Subjects undergo sputum culture baseline monthly treatment , initially absence anti-NTM therapy intent treat antibiotic persistence infection culture . Other clinical outcome include change sweat chloride , lung function weight . Safety measure include periodic assessment liver enzyme . All serious non-serious adverse event collect</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Subjects &gt; 18 year age able provide inform consent . Subjects reside US willing treated ivacaftor . Subjects splice mutation interest . Subjects willing able perform requirement study . There relevant exclusion criterion nof2 study .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>